Initiator Pharma A/S (STO:INIT)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.090
-0.010 (-0.32%)
Feb 26, 2026, 5:29 PM CET
Market Cap211.52M -46.9%
Revenue (ttm)n/a
Net Income-19.83M
EPS-0.32
Shares Out68.45M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume105,142
Average Volume80,163
Open3.110
Previous Close3.100
Day's Range3.050 - 3.240
52-Week Range2.560 - 8.000
Beta0.10
RSI50.26
Earnings DateFeb 20, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 2
Stock Exchange Nasdaq Stockholm
Ticker Symbol INIT
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements